Our data suggest that the anti-tumor activity of this combination therapy involves the reduced expression of EGFR, Ki-67 and CD31, therefore demonstrating anti-proliferative and anti-antiangiogenic effects with low toxicity. The gene discussed is EGFR; the disease is neoplasm.